Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × mCRPC × enzalutamide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 59 Breast Neoplasms 9 Neoplasm Metastasis 7 Prostatic Neoplasms, Castration-Resistant 6 Neoplasms 4 Prostate Cancer Metastatic 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Metastatic Castration-resistant Prostate Cancer 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration Resistant Prostate Cancer 2 Melanoma 2 mCRPC 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Ureteral Diseases 1 Small Cell Lung Carcinoma 1 Seizures 1 Salivary Cancer 1 Recurrent Endometrial Endometrioid Adenocarcinoma 1 Pancreatic Neoplasms 1 Neoplasms, Squamous Cell 1 Metastatic Progressive Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castrate-Resistant Prostate Cancer 1 Mesothelioma 1 Lymphoma, Mantle-Cell 1

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡